Co-Diagnostics, Inc. (CODX)

Develops molecular diagnostic tests for infectious diseases, focusing on rapid and accurate detection.

CODX Stock Quote

Company Report

Co-Diagnostics, Inc. is a pioneering molecular diagnostics company specializing in the development, manufacturing, and global distribution of reagents essential for diagnostic tests. These tests operate by detecting and analyzing nucleic acid molecules, catering to a diverse range of applications in the United States and abroad.

The company's innovative product portfolio includes polymerase chain reaction (PCR) diagnostic tests designed for detecting COVID-19, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. Co-Diagnostics also offers multiplexed tests for identifying diseases carried by mosquitoes, alongside molecular tools crucial for infectious disease detection, liquid biopsy for cancer screening, and agricultural applications.

Co-Diagnostics, Inc. is at the forefront of technological advancement with its portable PCR device, designed to facilitate PCR testing in point-of-care and home settings. Beyond its proprietary developments, the company plans to expand its offerings by incorporating diagnostic equipment from other manufacturers into self-contained lab systems. Founded in 2013 and headquartered in Salt Lake City, Utah, Co-Diagnostics continues to drive innovation in molecular diagnostics, aiming to enhance global healthcare outcomes through advanced diagnostic solutions.

CODX EPS Chart

CODX Revenue Chart

Stock Research

ASAI VLD PDD DEI UK OMAB KWR

CODX Chart

View interactive chart for CODX

CODX Profile

CODX News

Analyst Ratings